Yes, CNS is a massive field, particularly in disease areas with high unmet need and huge patient populations.
Of course, the resources required to take a drug through clinic in an indication like this would be well beyond PYC, but even as a preclinical asset, there could be an attraction to a large pharma.
As an example, there was the ASO in neurological disease collaboration forged between Ionis and Biogen in April 2018, for which Biogen stumped up $1 bn.
In December I posted on Biogen’s decision to exercise an option to one of the drugs being developed under this collaboration - IONIS-MAPTRx - which is targeting Alzheimer’s and is currently in Phase 1 extension. It’s administered by once-monthly intrathecal injection.
Not to be forgotten though, is that neurology is a particularly difficult therapeutic area with higher than usual failure rates and that the path to developing a successful drug for Alzheimer’s has frustrated every attempt to date.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)